Equities analysts expect that Heska Corp (NASDAQ:HSKA) will post sales of $41.14 million for the current quarter, according to Zacks. Two analysts have issued estimates for Heska’s earnings. The highest sales estimate is $41.38 million and the lowest is $40.91 million. Heska posted sales of $39.54 million in the same quarter last year, which would indicate a positive year over year growth rate of 4%. The firm is expected to report its next earnings report on Tuesday, February 27th.

According to Zacks, analysts expect that Heska will report full year sales of $41.14 million for the current year, with estimates ranging from $137.06 million to $138.00 million. For the next fiscal year, analysts anticipate that the firm will post sales of $154.17 million per share, with estimates ranging from $152.90 million to $155.21 million. Zacks’ sales averages are an average based on a survey of analysts that cover Heska.

Heska (NASDAQ:HSKA) last issued its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.03. The business had revenue of $31.40 million for the quarter, compared to analysts’ expectations of $36.10 million. Heska had a return on equity of 15.35% and a net margin of 10.67%. The firm’s quarterly revenue was down 6.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.45 EPS.

A number of brokerages recently issued reports on HSKA. BidaskClub cut Heska from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Zacks Investment Research cut Heska from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Aegis reissued a “buy” rating on shares of Heska in a report on Tuesday, December 19th. Raymond James Financial reissued a “buy” rating on shares of Heska in a report on Monday, December 4th. Finally, B. Riley dropped their price objective on Heska from $96.50 to $93.00 and set a “neutral” rating on the stock in a report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $113.30.

Shares of Heska (NASDAQ:HSKA) traded down $1.04 on Monday, reaching $76.72. The company had a trading volume of 64,200 shares, compared to its average volume of 51,325. The stock has a market cap of $555.74, a PE ratio of 40.17, a price-to-earnings-growth ratio of 2.02 and a beta of 0.74. Heska has a twelve month low of $72.44 and a twelve month high of $115.00.

In other Heska news, insider Michael J. Mcginley sold 7,826 shares of the company’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $87.14, for a total value of $681,957.64. Following the transaction, the insider now directly owns 106,771 shares in the company, valued at approximately $9,304,024.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.70% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in HSKA. Royal Bank of Canada increased its stake in Heska by 96.9% in the 2nd quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock worth $103,000 after acquiring an additional 499 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Heska during the 3rd quarter valued at about $108,000. Victory Capital Management Inc. increased its position in shares of Heska by 17.5% during the 2nd quarter. Victory Capital Management Inc. now owns 1,133 shares of the medical research company’s stock valued at $116,000 after purchasing an additional 169 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in shares of Heska by 59.2% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 1,858 shares of the medical research company’s stock valued at $190,000 after purchasing an additional 691 shares during the last quarter. Finally, D.A. Davidson & CO. increased its position in shares of Heska by 0.3% during the 2nd quarter. D.A. Davidson & CO. now owns 1,943 shares of the medical research company’s stock valued at $198,000 after purchasing an additional 5 shares during the last quarter. Institutional investors and hedge funds own 80.89% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Brokerages Expect Heska Corp (HSKA) Will Post Quarterly Sales of $41.14 Million” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/08/brokerages-expect-heska-corp-hska-will-post-quarterly-sales-of-41-14-million.html.

About Heska

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Get a free copy of the Zacks research report on Heska (HSKA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.